Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Accumulated Expenses (2023 - 2025)

Camp4 Therapeutics' Accumulated Expenses history spans 3 years, with the latest figure at $5.6 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 16.53% year-over-year to $5.6 million; the TTM value through Dec 2025 reached $5.6 million, up 16.53%, while the annual FY2025 figure was $5.6 million, 16.53% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $5.6 million at Camp4 Therapeutics, up from $4.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $5.6 million in Q4 2025 and bottomed at $3.3 million in Q4 2023.
  • The 3-year median for Accumulated Expenses is $4.3 million (2024), against an average of $4.4 million.
  • The largest annual shift saw Accumulated Expenses surged 46.37% in 2024 before it rose 16.53% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $3.3 million in 2023, then soared by 46.37% to $4.8 million in 2024, then rose by 16.53% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for CAMP's Accumulated Expenses are $5.6 million (Q4 2025), $4.8 million (Q4 2024), and $3.7 million (Q3 2024).